Imanis Life Sciences

Executive Summary

Imanis Life Sciences is a US-based contract research organization (CRO) specializing in virology, immunology, and molecular biology to support the development of next-generation therapies in oncology, infectious disease, gene therapy, and vaccine development. Founded in 2015 and headquartered in Rochester, New York, the company offers comprehensive preclinical research services, custom cell line and viral vector engineering, and a portfolio of specialized assays. Notable commercial products include the SPOTCOV and IMMUNO-COV COVID-19 antibody tests. The company serves a broad client base in the biopharmaceutical industry, leveraging its expertise in reporter cell lines and assay development to accelerate drug discovery and development timelines. As a private entity, Imanis Life Sciences focuses on generating revenue through service contracts and product sales, positioning itself as a key partner for biotech and pharmaceutical companies seeking outsourced research and development capabilities.

Upcoming Catalysts (preview)

• Q3 2026Launch of new gene therapy vector engineering service70% success
• Q4 2026Major contract award from top-20 pharma for oncology assay services50% success
• TBDFDA renewal or expansion of EUA for COVID-19 antibody tests40% success